EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Prime editing: A gene precision editing tool from inception to present

Zhihao Liu iD, Dong Guo iD, Dawei Wang iD, Jinglin Zhou iD, Qi Chen iD, Junzhong Lai iD

The FASEB Journal · 15.11.2024 · 38 (21)

DOI: 10.1096/fj.202401692r ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 12.11.2024. Verfasst von Zhihao Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University Qishan …. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 140 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Excellent Young Scholars Cultivation Project of Fujian Medical University Union Hospital in China, Fujian Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic mutations significantly contribute to the onset of diseases, with over half of the cases caused by single‐nucleotide mutations. Advances in gene editing technologies have enabled precise editing and correction of mutated genes, offering effective treatment methods for genetic disorders. CRISPR/Cas9, despite its power, poses risks of inducing gene mutations due to DNA double‐strand breaks (DSB). The advent of base editing (BE) and prime editing (PE) has mitigated these risks by eliminating the hazards associated with DNA DSBs, allowing for more precise gene editing. This breakthrough lays a solid foundation for the clinical application of gene editing technologies. This review discusses the principles, development, and applications of PE gene editing technology in various genetic mutation‐induced diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingCRISPR-Cas SystemsHumansDNA Breaks, Double-StrandedAnimalsGenetic TherapyMutation

Stichwörter der Autor:innen

CRISPR/Cas9gene editinggene therapyprime editing

Autor:innen und Institutionen

  • Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University Qishan Campus, Fuzhou, PR China.
  • The Cancer Center, Fujian Medical University Union Hospital, Fuzhou, PR China.

ORCID-Profile: Zhihao Liu, Dong Guo, Dawei Wang, Jinglin Zhou, Qi Chen, Junzhong Lai

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)
  • Excellent Young Scholars Cultivation Project of Fujian Medical University Union Hospital in China
  • Fujian Provincial Natural Science Foundation of China
  • National Natural Science Foundation of China (NSFC)

Zitieren

APA

Liu, Z., Guo, D., Wang, D., Zhou, J., Chen, Q., & Lai, J. (2024). Prime editing: A gene precision editing tool from inception to present. The FASEB Journal, 38(21). https://doi.org/10.1096/fj.202401692r

Vancouver

Liu Z, Guo D, Wang D, Zhou J, Chen Q, Lai J. Prime editing: A gene precision editing tool from inception to present. The FASEB Journal. 2024;38(21). doi:10.1096/fj.202401692r

BibTeX
@article{Liu2024,
  author = {Liu, Zhihao and Guo, Dong and Wang, Dawei and Zhou, Jinglin and Chen, Qi and Lai, Junzhong},
  title = {Prime editing: A gene precision editing tool from inception to present},
  journal = {The FASEB Journal},
  year = {2024},
  volume = {38},
  number = {21},
  doi = {10.1096/fj.202401692r}
}
Kostenlos starten →